BPMC (Blueprint Medicines) Land And Improvements : $0.0 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Land And Improvements?

Blueprint Medicines's land and improvements for the quarter that ended in Dec. 2024 was $0.0 Mil.

Blueprint Medicines Land And Improvements Historical Data

The historical data trend for Blueprint Medicines's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Land And Improvements Chart

Blueprint Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Get a 7-Day Free Trial

Blueprint Medicines Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Blueprint Medicines Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Blueprint Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

0HOJ:UK 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Executives

Christina Rossi	officer: Chief Commercial Officer	45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Jeffrey W. Albers	director, officer: CEO & President	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Kate Haviland	officer: Chief Business Officer	BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Ariel Hurley	officer: Principal Accounting Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Lonnel Coats	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Fouad Namouni	officer: President, R and D	535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
Michael Landsittel	officer: Principal FAO	BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Philina Lee	officer: Chief Commercial Officer	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Debra Durso-bumpus	officer: Chief People Officer	C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Percy H. Carter	officer: Chief Scientific Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
L. Becker Hewes	officer: Chief Medical Officer	C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Christopher K. Murray	officer: SVP, Technical Operations	C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Tracey L Mccain	officer: EVP and Chief Legal Officer	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai	director	BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139